ASX:PARParadigm Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$2.41 -0.07 (-2.82 %) (As of 05/13/2020) Add Compare Share Today's RangeA$2.33Now: A$2.41▼A$2.4550-Day RangeA$1.44MA: A$1.98▼A$2.7052-Week RangeA$1.08Now: A$2.41▼A$4.50Volume1.81 million shsAverage VolumeN/AMarket Capitalization$476.73 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesOptions Chain Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company has a strategic partnership with the Pro Players' Elite Network to identify and assist sportspeople that have existing knee and joint pathologies that would benefit from treatment with injectable Pentosan Polysulfate Sodium. Paradigm Biopharmaceuticals Limited was incorporated in 2014 and is based in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Paradigm Biopharmaceuticals. Previous Next 3.0 Community Rank Outperform VotesParadigm Biopharmaceuticals has received 32 “outperform” votes. (Add your “outperform” vote.)Underperform VotesParadigm Biopharmaceuticals has received 21 “underperform” votes. (Add your “underperform” vote.)Community SentimentParadigm Biopharmaceuticals has received 60.38% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Paradigm Biopharmaceuticals and other stocks. Vote “Outperform” if you believe PAR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldParadigm Biopharmaceuticals does not currently pay a dividend.Dividend GrowthParadigm Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paradigm Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought A$0.00 in company stock and sold A$697,778.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Paradigm Biopharmaceuticals is -25.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paradigm Biopharmaceuticals is -25.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioParadigm Biopharmaceuticals has a P/B Ratio of 5.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:PAR Previous Symbol CUSIPN/A CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566Debt Debt-to-Equity Ratio1.17 Current Ratio66.64 Quick Ratio66.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.78 million Price / Sales126.06 Cash FlowA$0.37 per share Price / Cash Flow6.44 Book ValueA$0.40 per share Price / Book5.98Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares197,814,000Market Cap$476.73 million Next Earnings DateN/A OptionableOptionable Receive PAR News and Ratings via Email Sign-up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter. Paradigm Biopharmaceuticals (ASX:PAR) Frequently Asked Questions How has Paradigm Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Paradigm Biopharmaceuticals' stock was trading at A$2.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PAR stock has increased by 1.3% and is now trading at A$2.41. View which stocks have been most impacted by Coronavirus. Has Paradigm Biopharmaceuticals been receiving favorable news coverage? News headlines about PAR stock have been trending positive recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Paradigm Biopharmaceuticals earned a news impact score of 2.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutParadigm Biopharmaceuticals. Who are some of Paradigm Biopharmaceuticals' key competitors? Some companies that are related to Paradigm Biopharmaceuticals include Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Aptose Biosciences (APS), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA) and Biotest (BIO). View all competitors. What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Envirosuite (EVS), Bubs Australia (BUB), BHP Group (BHP), Avita Medical (AVH), Afterpay Touch Group (APT), Alcidion Group (ALC), A2 Milk (A2M) and 8Common (8CO). Who are Paradigm Biopharmaceuticals' key executives? Paradigm Biopharmaceuticals' management team includes the following people: Mr. Paul Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Exec. Director (Age 60)Mr. Kevin G. Hollingsworth, CFO & Company Sec. (Age 66)Dr. Claire Kaufman, Chief Operations OfficerDr. Ravi Krishnan, Chief Scientific Officer What is Paradigm Biopharmaceuticals' stock symbol? Paradigm Biopharmaceuticals trades on the ASX under the ticker symbol "PAR." What is Paradigm Biopharmaceuticals' stock price today? One share of PAR stock can currently be purchased for approximately A$2.41. How big of a company is Paradigm Biopharmaceuticals? Paradigm Biopharmaceuticals has a market capitalization of $476.73 million and generates $3.78 million in revenue each year. What is Paradigm Biopharmaceuticals' official website? The official website for Paradigm Biopharmaceuticals is www.paradigmbiopharma.com. How can I contact Paradigm Biopharmaceuticals? The company can be reached via phone at 61 3 9629 5566. This page was last updated on 5/28/2020 by MarketBeat.com Staff
